Literature DB >> 3016710

Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.

S Torsteinsdottir, M G Masucci, B Ehlin-Henriksson, C Brautbar, H Ben Bassat, G Klein, E Klein.   

Abstract

Sets of Burkitt lymphoma lines and Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) derived from the same individuals were compared for sensitivity to cytotoxic T-lymphocyte (CTL) clones. Major histocompatibility complex class I antigen-restricted CTL clones were generated by stimulating the lymphocytes of an EBV-seropositive individual with the autologous LCL. One clone (BK-20) lysed the autologous and allogeneic HLA-A11-expressing LCLs but not mitogen-induced B lymphoblasts. Thus the clone was selectively cytotoxic for LCLs. Allospecific CTL clones directed against the HLA-A11 antigen were generated from an EBV-seronegative individual. One clone (WP-36) was selectively cytotoxic for the appropriate allospecific LCL, whereas another clone (WP-21) lysed also T and B lymphoblasts. None of the four Burkitt lymphoma lines established in parallel with the CTL-sensitive LCLs were lysed. Two of the Burkitt lymphoma lines were EBV-negative, and EBV-positive sublines were derived from these by in vitro infection. One but not the other of the two convertants became sensitive to all three types of CTL clones. The CTL-sensitive converted line had also acquired some LCL characteristics: increased cell size, aggregation, and a shift in several of the B-cell-specific surface markers. The CTL-resistant convertant expressed EBV antigens but showed no phenotypic change. These findings suggest that the cellular phenotype plays a decisive role in the sensitivity of B-cell-derived lines to the lytic effect of LCL-selective autologous and allogeneic CTLs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3016710      PMCID: PMC386340          DOI: 10.1073/pnas.83.15.5620

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma.

Authors:  M Rowe; C M Rooney; A B Rickinson; G M Lenoir; H Rupani; D J Moss; H Stein; M A Epstein
Journal:  Int J Cancer       Date:  1985-04-15       Impact factor: 7.396

2.  Establishment of lymphomatous cell lines from bone marrow samples from patients with Burkitt's lymphoma.

Authors:  I Philip; T Philip; M Favrot; M Vuillaume; B Fontaniere; D Chamard; G M Lenoir
Journal:  J Natl Cancer Inst       Date:  1984-10       Impact factor: 13.506

Review 3.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma.

Authors:  K Nilsson; G Klein
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

4.  Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.

Authors:  M C Favrot; I Philip; T Philip; J Portoukalian; J F Doré; G M Lenoir
Journal:  J Natl Cancer Inst       Date:  1984-10       Impact factor: 13.506

5.  Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma.

Authors:  M Rowe; C M Rooney; C F Edwards; G M Lenoir; A B Rickinson
Journal:  Int J Cancer       Date:  1986-03-15       Impact factor: 7.396

6.  Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers.

Authors:  S Torsteinsdottir; M G Masucci; G Lenoir; G Klein; E Klein
Journal:  Cell Immunol       Date:  1984-07       Impact factor: 4.868

7.  Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro.

Authors:  C M Rooney; A B Rickinson; D J Moss; G M Lenoir; M A Epstein
Journal:  Int J Cancer       Date:  1984-09-15       Impact factor: 7.396

8.  Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.

Authors:  C M Rooney; M Rowe; L E Wallace; A B Rickinson
Journal:  Nature       Date:  1985 Oct 17-23       Impact factor: 49.962

9.  Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias.

Authors:  G Klein; A Manneborg-Sandlund; B Ehlin-Henriksson; T Godal; J Wiels; T Tursz
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

10.  Epstein-Barr virus-specific cytotoxic T lymphocytes as probes of HLA polymorphism. Heterogeneity of T cell-restricting determinants associated with the serologically defined HLA-A2 antigen.

Authors:  J S Gaston; A B Rickinson; M A Epstein
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  23 in total

1.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

Authors:  R Gavioli; P O De Campos-Lima; M G Kurilla; E Kieff; G Klein; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.

Authors:  R J Murray; L S Young; A Calender; C D Gregory; M Rowe; G M Lenoir; A B Rickinson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.

Authors:  I Bourgault; A Gomez; E Gomard; J P Levy
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

Authors:  Diego Marescotti; Federica Destro; Anna Baldisserotto; Mauro Marastoni; Giuseppe Coppotelli; Maria Masucci; Riccardo Gavioli
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

5.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein.

Authors:  D A Thorley-Lawson; E S Israelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.

Authors:  M G Masucci; S Torsteindottir; J Colombani; C Brautbar; E Klein; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

8.  Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.

Authors:  P Trivedi; P Spinsanti; L Cuomo; M Volpe; K Takada; L Frati; A Faggioni
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 9.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

Review 10.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.